Organization (Industry)
BECTON, DICKINSON AND COMPANY
ClinicalTrials.gov lists BECTON, DICKINSON AND COMPANY as lead sponsor of 184 trials, counting the companies grouped under it. BECTON, DICKINSON AND COMPANY itself has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 8 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo BD (company), via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BECTON, DICKINSON AND COMPANY and 10 companies grouped under it: 184 lead-sponsored trials (61 its own, 123 in the grouped companies) and 17 legal-entity registrations (3 its own, 14 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (10)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| C. R. Bard | 117 | 0 |
| Straub Medical (Switzerland) | 4 | 1 |
| Clearstream Technologies Ltd. | 1 | 0 |
| Velano Vascular, Inc. | 1 | 0 |
| BD Switzerland Sàrl | 0 | 1 |
Showing 5 of 10 member companies.
Disease areas (104)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 24 |
| Atherosclerosis | 20 |
| Peripheral Arterial Disease | 19 |
| Diabetes Mellitus, Type 1 | 15 |
| Renal Insufficiency, Chronic | 12 |
Showing 5 of 104 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 8 |
| 2024 | 4 |
| 2023 | 4 |
| 2022 | 8 |
| 2021 | 13 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 2 |
| 2017 | 5 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ChloraPrep | 1 |
| Insulin LISPRO | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 73% hit target (n=26) | 32% on time (n=25) |
Journals published in (187)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of vascular surgery | 21 |
| The New England journal of medicine | 17 |
| JAMA | 11 |
| Circulation | 10 |
| Diabetes technology & therapeutics | 7 |
Showing 5 of 187 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 6,977 | 1,312 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 21,840,000,000 | 1,678,000,000 | 1,265,000,000 |
| 2024 | 20,178,000,000 | 1,705,000,000 | 1,190,000,000 |
| 2023 | 19,372,000,000 | 1,484,000,000 | 1,237,000,000 |
| 2022 | 18,870,000,000 | 1,779,000,000 | 1,256,000,000 |
| 2021 | 19,131,000,000 | 2,092,000,000 | 1,279,000,000 |
| 2020 | 16,074,000,000 | 874,000,000 | 1,039,000,000 |
| 2019 | 17,290,000,000 | 1,233,000,000 | 1,062,000,000 |
| 2018 | 15,983,000,000 | 311,000,000 | 1,004,000,000 |
| 2017 | 12,093,000,000 | 1,100,000,000 | 770,000,000 |
| 2016 | 12,483,000,000 | 976,000,000 | 828,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (96)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-20 | Debt financing | not disclosed | Sec extracted |
| 2026-05-13 | Other financing | not disclosed | Edgar offerings |
| 2026-05-11 | Other financing | not disclosed | Edgar offerings |
| 2026-05-11 | Debt financing | not disclosed | Sec extracted |
| 2026-02-25 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 96 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (10)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Medtronic plc | Co sponsors trial with | 1 |
| Diabetes Canada | Co sponsors trial with | 1 |
| Breakthrough T1D | Co sponsors trial with | 1 |
| University of Virginia | Co sponsors trial with | 1 |
| University of Edinburgh | Co sponsors trial with | 1 |
Showing 5 of 10 relationships.
Latest dated events (7,498)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 7,498 events.
Biomarker capability evidence (59)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACSBG1 | Trial sponsor | Named in trial inclusion criteria |
| ACSBG1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BCL2L10 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 59 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: active development programs, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.